Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment
- Conditions
- Hereditary Cancer SyndromeGynecologic Cancer
- Interventions
- Other: Chatbot
- Registration Number
- NCT05562778
- Lead Sponsor
- Weill Medical College of Cornell University
- Brief Summary
In this study, the investigators aim to compare a mobile health platform, known as a 'chatbot,' that leverages artificial intelligence and natural language processing to scale communication, to 'usual care' that patients would receive. This comparison will enable the investigators to determine if the chatbot system can improve rates of recommendation for genetic testing among patients at elevated risk of harboring a familial cancer syndrome in an all-Medicaid gynecology clinic. Furthermore, the investigators aim to evaluate facilitators of inequity in regard to patient access to and utilization of genetic testing services.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 150
- 8 years of age or older.
- Scheduled for a New Patient appointment in the gynecology clinic. Speaks and reads in English.
- Access to a telephone with texting capacity.
- Has not had prior genetic testing for hereditary cancer syndromes.
- Under 18 years of age
- Has had previous genetic testing for hereditary cancer syndromes
- Does not read/speak in English
- Does not have access to a phone with texting capabilities
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Chatbot Chatbot Subjects will receive a text message initiating a chatbot conversation that relies on natural language processing to gather personal and family cancer. Subjects are identified by the chatbot as meeting National Comprehensive Cancer Network (NCCN) high-risk criteria. Next, subjects undergo pre-test genetic counseling via the chatbot and then clinicians are notified (via the chatbot portal) that the subject meets high-risk criteria. For subjects meeting high-risk criteria (based on the chatbot evaluation), the clinician will complete genetic counseling and recommend genetic testing during the visit. For subjects interested in genetic testing, the clinician will order genetic testing.
- Primary Outcome Measures
Name Time Method Proportion recommended genetic testing 2 years The proportion of high-risk patients that are recommended genetic testing for familial cancer syndromes in the chatbot vs. usual care arms.
- Secondary Outcome Measures
Name Time Method Facilitator of inequity in the utilization of genetic services 2 years The specific facilitators of inequity that affect the utilization of genetic testing services, among high-risk patients who decline recommended genetic testing. Examples of these facilitators include patient race, ethnicity, affordability, and social determinants of health. The validated survey known as the Patient Reported Utility (PrU) survey will enable these patients to identify various facilitators that influenced their decision not to complete genetic testing. Specifically, the Patient Reported Utility (PrU) that assesses how useful patients found certain outcomes of their test results, ranking from 1 (not at all useful) to 7 (extremely useful).
Proportion completed recommended genetic testing 2 years The proportion of high-risk patients who complete recommended genetic testing for familial cancer syndromes in the chatbot vs. usual care arms.
Barriers to genetic testing 2 years The barriers (as identified through qualitative interviews) to genetic testing among high-risk patients who decline recommended genetic testing.
Trial Locations
- Locations (4)
Weill Cornell Medicine
🇺🇸New York, New York, United States
NYP Medical Group Queens
🇺🇸Queens, New York, United States
NYP Brooklyn Methodist Hospital
🇺🇸Brooklyn, New York, United States
NYP Lower Manhattan Hospital
🇺🇸New York, New York, United States